Logo image of MRX.DE

MISTER SPEX SE (MRX.DE) Stock Fundamental Analysis

FRA:MRX - Deutsche Boerse Ag - DE000A3CSAE2 - Common Stock - Currency: EUR

1.47  -0.01 (-0.68%)

Fundamental Rating

2

Overall MRX gets a fundamental rating of 2 out of 10. We evaluated MRX against 51 industry peers in the Specialty Retail industry. MRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year MRX has reported negative net income.
MRX had a negative operating cash flow in the past year.
MRX had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: MRX reported negative operating cash flow in multiple years.
MRX.DE Yearly Net Income VS EBIT VS OCF VS FCFMRX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

MRX's Return On Assets of -23.46% is on the low side compared to the rest of the industry. MRX is outperformed by 86.00% of its industry peers.
MRX has a worse Return On Equity (-44.25%) than 82.00% of its industry peers.
Industry RankSector Rank
ROA -23.46%
ROE -44.25%
ROIC N/A
ROA(3y)-14.03%
ROA(5y)-11.64%
ROE(3y)-22.01%
ROE(5y)-25.74%
ROIC(3y)N/A
ROIC(5y)N/A
MRX.DE Yearly ROA, ROE, ROICMRX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

MRX's Gross Margin of 52.57% is fine compared to the rest of the industry. MRX outperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of MRX has grown nicely.
MRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y1.76%
MRX.DE Yearly Profit, Operating, Gross MarginsMRX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

4

2. Health

2.1 Basic Checks

MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRX has more shares outstanding
Compared to 5 years ago, MRX has more shares outstanding
Compared to 1 year ago, MRX has a worse debt to assets ratio.
MRX.DE Yearly Shares OutstandingMRX.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
MRX.DE Yearly Total Debt VS Total AssetsMRX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.53, we must say that MRX is in the distress zone and has some risk of bankruptcy.
MRX's Altman-Z score of -0.53 is on the low side compared to the rest of the industry. MRX is outperformed by 74.00% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that MRX is not too dependend on debt financing.
The Debt to Equity ratio of MRX (0.49) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -0.53
ROIC/WACCN/A
WACC5.08%
MRX.DE Yearly LT Debt VS Equity VS FCFMRX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 3.04 indicates that MRX has no problem at all paying its short term obligations.
The Current ratio of MRX (3.04) is better than 90.00% of its industry peers.
A Quick Ratio of 2.24 indicates that MRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.24, MRX belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.24
MRX.DE Yearly Current Assets VS Current LiabilitesMRX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

4

3. Growth

3.1 Past

The earnings per share for MRX have decreased strongly by -20.77% in the last year.
MRX shows a small growth in Revenue. In the last year, the Revenue has grown by 1.30%.
The Revenue has been growing by 12.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.86%
Revenue 1Y (TTM)1.3%
Revenue growth 3Y10.83%
Revenue growth 5Y12.73%
Sales Q2Q%-3.17%

3.2 Future

MRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.00% yearly.
The Revenue is expected to grow by 8.66% on average over the next years. This is quite good.
EPS Next Y-86.57%
EPS Next 2Y2.85%
EPS Next 3Y13.18%
EPS Next 5Y14%
Revenue Next Year-2.59%
Revenue Next 2Y-5.08%
Revenue Next 3Y-2.37%
Revenue Next 5Y8.66%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MRX.DE Yearly Revenue VS EstimatesMRX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
MRX.DE Yearly EPS VS EstimatesMRX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRX. In the last year negative earnings were reported.
Also next year MRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRX.DE Price Earnings VS Forward Price EarningsMRX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRX.DE Per share dataMRX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

MRX's earnings are expected to grow with 13.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.85%
EPS Next 3Y13.18%

0

5. Dividend

5.1 Amount

No dividends for MRX!.
Industry RankSector Rank
Dividend Yield N/A

MISTER SPEX SE

FRA:MRX (5/2/2025, 7:00:00 PM)

1.47

-0.01 (-0.68%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)05-08 2024-05-08/amc
Earnings (Next)N/A N/A
Inst Owners25.4%
Inst Owner ChangeN/A
Ins Owners3.98%
Ins Owner ChangeN/A
Market Cap51.52M
Analysts77.5
Price Target4.23 (187.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.21%
PT rev (3m)-20.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS6.37
BVpS3.56
TBVpS2.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.46%
ROE -44.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.57%
FCFM N/A
ROA(3y)-14.03%
ROA(5y)-11.64%
ROE(3y)-22.01%
ROE(5y)-25.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y1.76%
F-Score4
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.75%
Cap/Sales 3.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.24
Altman-Z -0.53
F-Score4
WACC5.08%
ROIC/WACCN/A
Cap/Depr(3y)72.39%
Cap/Depr(5y)88.93%
Cap/Sales(3y)8.02%
Cap/Sales(5y)7.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.86%
EPS Next Y-86.57%
EPS Next 2Y2.85%
EPS Next 3Y13.18%
EPS Next 5Y14%
Revenue 1Y (TTM)1.3%
Revenue growth 3Y10.83%
Revenue growth 5Y12.73%
Sales Q2Q%-3.17%
Revenue Next Year-2.59%
Revenue Next 2Y-5.08%
Revenue Next 3Y-2.37%
Revenue Next 5Y8.66%
EBIT growth 1Y-25.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.11%
EBIT Next 3Y33.03%
EBIT Next 5Y28.78%
FCF growth 1Y48.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.05%
OCF growth 3YN/A
OCF growth 5YN/A